Your browser doesn't support javascript.
loading
A comprehensive AI model development framework for consistent Gleason grading.
Huo, Xinmi; Ong, Kok Haur; Lau, Kah Weng; Gole, Laurent; Young, David M; Tan, Char Loo; Zhu, Xiaohui; Zhang, Chongchong; Zhang, Yonghui; Li, Longjie; Han, Hao; Lu, Haoda; Zhang, Jing; Hou, Jun; Zhao, Huanfen; Gan, Hualei; Yin, Lijuan; Wang, Xingxing; Chen, Xiaoyue; Lv, Hong; Cao, Haotian; Yu, Xiaozhen; Shi, Yabin; Huang, Ziling; Marini, Gabriel; Xu, Jun; Liu, Bingxian; Chen, Bingxian; Wang, Qiang; Gui, Kun; Shi, Wenzhao; Sun, Yingying; Chen, Wanyuan; Cao, Dalong; Sanders, Stephan J; Lee, Hwee Kuan; Hue, Susan Swee-Shan; Yu, Weimiao; Tan, Soo Yong.
Afiliación
  • Huo X; Computational Digital Pathology Lab, Bioinformatics Institute, A*STAR, Singapore, Singapore.
  • Ong KH; Computational Digital Pathology Lab, Bioinformatics Institute, A*STAR, Singapore, Singapore.
  • Lau KW; Computational & Molecular Pathology Lab, Institute of Molecule and Cell Biology, A*STAR, Singapore, Singapore.
  • Gole L; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore.
  • Young DM; Computational & Molecular Pathology Lab, Institute of Molecule and Cell Biology, A*STAR, Singapore, Singapore.
  • Tan CL; Computational & Molecular Pathology Lab, Institute of Molecule and Cell Biology, A*STAR, Singapore, Singapore.
  • Zhu X; Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California, San Francisco, USA.
  • Zhang C; Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore.
  • Zhang Y; Department of Pathology, Nanfang Hospital and Basic Medical College, Southern Medical University, Guangzhou, Guangdong Province, China.
  • Li L; Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou, Guangdong Province, China.
  • Han H; Department of Pathology, The 910 Hospital of PLA, QuanZhou, Fujian Province, China.
  • Lu H; Department of Pathology, The 910 Hospital of PLA, QuanZhou, Fujian Province, China.
  • Zhang J; Computational Digital Pathology Lab, Bioinformatics Institute, A*STAR, Singapore, Singapore.
  • Hou J; Computational & Molecular Pathology Lab, Institute of Molecule and Cell Biology, A*STAR, Singapore, Singapore.
  • Zhao H; Computational Digital Pathology Lab, Bioinformatics Institute, A*STAR, Singapore, Singapore.
  • Gan H; Institute for AI in Medicine, School of Artificial Intelligence, Nanjing University of Information Science and Technology (NUIST), Nanjing, Jiangsu Province, China.
  • Yin L; Department of Pathology, Shanghai Changzheng Hospital, Shanghai, China.
  • Wang X; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Chen X; Department of Pathology, Hebei General Hospital, Shijiazhuang, Hebei Province, China.
  • Lv H; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Cao H; Department of Pathology, Changhai Hospital of Shanghai, Shanghai, China.
  • Yu X; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shi Y; Department of Pathology, Hebei General Hospital, Shijiazhuang, Hebei Province, China.
  • Huang Z; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Marini G; Department of Pathology, Shanghai Changzheng Hospital, Shanghai, China.
  • Xu J; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Liu B; Department of Pathology, Hebei General Hospital, Shijiazhuang, Hebei Province, China.
  • Chen B; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Wang Q; Computational Digital Pathology Lab, Bioinformatics Institute, A*STAR, Singapore, Singapore.
  • Gui K; Institute for AI in Medicine, School of Artificial Intelligence, Nanjing University of Information Science and Technology (NUIST), Nanjing, Jiangsu Province, China.
  • Shi W; Ningbo KonFoong Bioinformation Tech Co. Ltd, Ningbo, Zhejiang Province, China.
  • Sun Y; Ningbo KonFoong Bioinformation Tech Co. Ltd, Ningbo, Zhejiang Province, China.
  • Chen W; Ningbo KonFoong Bioinformation Tech Co. Ltd, Ningbo, Zhejiang Province, China.
  • Cao D; Ningbo KonFoong Bioinformation Tech Co. Ltd, Ningbo, Zhejiang Province, China.
  • Sanders SJ; Vishuo Biomedical Pte Ltd, Singapore, Singapore.
  • Lee HK; Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
  • Hue SS; Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
  • Yu W; Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang Province, China.
  • Tan SY; Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang Province, China.
Commun Med (Lond) ; 4(1): 84, 2024 May 09.
Article en En | MEDLINE | ID: mdl-38724730
ABSTRACT

BACKGROUND:

Artificial Intelligence(AI)-based solutions for Gleason grading hold promise for pathologists, while image quality inconsistency, continuous data integration needs, and limited generalizability hinder their adoption and scalability.

METHODS:

We present a comprehensive digital pathology workflow for AI-assisted Gleason grading. It incorporates A!MagQC (image quality control), A!HistoClouds (cloud-based annotation), Pathologist-AI Interaction (PAI) for continuous model improvement, Trained on Akoya-scanned images only, the model utilizes color augmentation and image appearance migration to address scanner variations. We evaluate it on Whole Slide Images (WSI) from another five scanners and conduct validations with pathologists to assess AI efficacy and PAI.

RESULTS:

Our model achieves an average F1 score of 0.80 on annotations and 0.71 Quadratic Weighted Kappa on WSIs for Akoya-scanned images. Applying our generalization solution increases the average F1 score for Gleason pattern detection from 0.73 to 0.88 on images from other scanners. The model accelerates Gleason scoring time by 43% while maintaining accuracy. Additionally, PAI improve annotation efficiency by 2.5 times and led to further improvements in model performance.

CONCLUSIONS:

This pipeline represents a notable advancement in AI-assisted Gleason grading for improved consistency, accuracy, and efficiency. Unlike previous methods limited by scanner specificity, our model achieves outstanding performance across diverse scanners. This improvement paves the way for its seamless integration into clinical workflows.
Gleason grading is a well-accepted diagnostic standard to assess the severity of prostate cancer in patients' tissue samples, based on how abnormal the cells in their prostate tumor look under a microscope. This process can be complex and time-consuming. We explore how artificial intelligence (AI) can help pathologists perform Gleason grading more efficiently and consistently. We build an AI-based system which automatically checks image quality, standardizes the appearance of images from different equipment, learns from pathologists' feedback, and constantly improves model performance. Testing shows that our approach achieves consistent results across different equipment and improves efficiency of the grading process. With further testing and implementation in the clinic, our approach could potentially improve prostate cancer diagnosis and management.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Commun Med (Lond) Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Commun Med (Lond) Año: 2024 Tipo del documento: Article